Lead Product(s) : HB-700
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Hookipa Pharma
Deal Size : Undisclosed
Deal Type : Merger
Poolbeg Pharma Plc Combination of Poolbeg and HOOKIPA Pharma Inc.
Details : The combined company will advance the next-generation immunotherapies including, multi-KRAS targeting HB-700, for the treatment of cancer and other serious diseases.
Product Name : HB-700
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 02, 2025
Lead Product(s) : HB-700
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Hookipa Pharma
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : AVA6103
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform
Details : AVA6103 is a Gen Two pre|CISION peptide drug conjugate, which is being evaluated for the treatment of gastric cancer, triple negative breast cancer & small cell lung cancer.
Product Name : AVA6103
Product Type : Peptide
Upfront Cash : Inapplicable
October 17, 2024
Lead Product(s) : AVA6103
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AST-201
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aptamer Sciences Files IND Application for AST-201, an Innovative Liver Cancer Treatment
Details : AST-201 is an aptamer-drug conjugate designed to target GPC3 protein, which exhibits high expression levels in specific cancer cells. It is being evaluated for the treatment of liver cancer.
Product Name : AST-201
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
March 25, 2024
Lead Product(s) : AST-201
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : M300
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors
Details : M300 is a first-in-class antibody program designed to conditionally induce the formation of tertiary lymphoid structures in the tumor. It is being evaluated for the treatment of solid tumors.
Product Name : M300
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 20, 2024
Lead Product(s) : M300
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Prevail Partners
Deal Size : $0.3 million
Deal Type : Financing
Hemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLC
Details : THe proceeds will be used in clinical services and technologies for the Company's upcoming Phase I of an anti-FLT3 CAR-T cells in pediatric subjects with R/R AML and a subset of ALL.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Prevail Partners
Deal Size : $0.3 million
Deal Type : Financing
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces CDX Development Update
Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanized monoclonal antibody. It is being evaluated in preclinical studies for the treatment of r/r acute myeloid leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 09, 2024
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces Submission of Complete Response to Clinical Hold
Details : HEMO-CAR-T cell therapy is developed using Hemogenyx’s proprietary humanised monoclonal antibody. It is being evaluated in preclinical studies for the treatment of acute myeloid leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CV6-168,Fluorouracil
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial
Details : CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase.
Product Name : CV6-168
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : CV6-168,Fluorouracil
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces Full FDA Review for HEMO-CAR-T IND
Details : HEMO-CAR-T is made using Hemogenyx’s proprietary humanised monoclonal antibody against a target on the surface of AML cells and potential treatment of Acute Myeloid Leukemia.
Product Name : HEMO-CAR-T
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 07, 2023
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hemogenyx Pharmaceuticals PLC Announces Submission of IND for HEMO-CAR-T
Details : HEMO-CAR-T is being clinically evaluated for treating acute myeloid leukemia (AML). CAR-T therapy is a treatment in which a patient’s own T-cells, a type of immune cell, are modified to recognize and kill the patient’s cancer cells.
Product Name : HEMO-CAR-T
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 05, 2023
Lead Product(s) : HEMO-CAR-T
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable